Natera (NTRA) Insider Lynch Thomas JR. Buys 1,905 Shares

Lynch Thomas JR. bought 1,905 shares of Natera, Inc. (NasdaqGS: NTRA) on June 26, 2026, at a price of $267.05 per share. This purchase adds to a growing list of insider trades at the company, signaling confidence from multiple executives. The total value of this transaction was not disclosed.

Inside Lynch Thomas JR.'s Trade

This acquisition continues a trend of insider buying at Natera, as Lynch Thomas JR. joins other executives in purchasing shares on the same day. Notably, Rowan Chapman purchased 1,674 shares, Roelof Botha acquired 1,691 shares, and Eric Rubin bought 75 shares on June 26. Roy Baynes also added 1,646 shares to his holdings. These trades reflect a collective belief in Natera's potential.

Other Institutional Activity in Natera, Inc.

Several other institutional investors have adjusted their positions in Natera. JPMorgan Chase & Co. reduced its holdings by 520,718 shares, ending with 12,865,346 shares worth about $5.03 billion. Blackrock Inc. added 237,042 shares for a total of 10,914,608 shares valued at roughly $4.27 billion. Price (T.Rowe) Associates Inc. decreased its stake by 3,163,268 shares, bringing its holdings to 9,021,895 shares worth about $3.53 billion. Vanguard Capital Management LLC grew its holdings by 219,904 shares, totaling 6,228,216 shares valued at approximately $2.44 billion. Lastly, Vanguard Portfolio Management LLC increased its stake by 137,736 shares, amounting to 5,782,640 shares worth around $2.26 billion.

Natera, Inc. Stock Down 34.0%

Natera's shares are currently trading at $267.05, significantly lower than their 52-week high of $373.07. The stock has seen considerable volatility, and while it sits below recent highs, today’s buying activity from insiders might indicate potential recovery. The stock has faced challenges but continues to attract interest from both insiders and analysts.

Recent Earnings

In its most recent earnings report, Natera generated $2.71 billion in revenue, reflecting a growth rate of 37.7%. However, the company reported a negative earnings per share (EPS) of -$1.37. The net margin stands at -7.1%, indicating ongoing financial challenges, but analysts expect this may improve in the future, with the next earnings date set for November 5, 2026.

Analysts Set New Price Targets

Analysts are optimistic about Natera's prospects, with several firms maintaining high ratings. On October 14, JP Morgan maintained an Overweight rating with a target price of $460, up from $360. Morgan Stanley also kept an Overweight rating, raising its target to $435 from $355 on October 13. TD Cowen maintained a Buy rating with a target of $480, reflecting confidence in the company's growth potential.

About Natera, Inc.

Natera, Inc. is a diagnostics company based in Austin, Texas. It focuses on developing and commercializing molecular testing services globally. The company’s offerings include personalized tests for cancer monitoring and genetic screening. This insider buying trend may indicate that executives believe strongly in Natera's growth trajectory and upcoming products.

Bottom Line

As Natera approaches its next earnings report on November 5, investors will be watching closely for signs of recovery. The recent insider activity, along with strong analyst ratings, suggests there may be more developments ahead. It's important to remember that the 13F filings reflect past positions and may not represent current holdings or intentions.